The investigation adds legal overhang to an already negative earnings and guidance miss. Traders should monitor for further stock declines as the investigation progresses and for any additional details on the neuroendocrine-tumor business ramp. The lowered guidance suggests near-term headwinds for the CABOMETYX franchise.
Price Chart
Executive Summary
Levi & Korsinsky announced an investigation into Exelixis (EXEL) regarding potentially misleading statements about full-year 2026 revenue guidance. The company reiterated guidance on May 5, 2026, but later lowered and narrowed that outlook after Q2 results, causing the stock to decline. Q2 2026 revenue of ~$628.7M missed consensus of $652.3M, and EPS of $0.82 missed the $0.91 estimate, marking a significant negative surprise that triggered the investigation.
Key Financial Metrics
Key Facts
- Levi & Korsinsky launched an investigation into Exelixis for potentially misleading statements regarding full-year 2026 revenue guidance.
- Exelixis reiterated full-year 2026 guidance on May 5, 2026, but later lowered and narrowed that outlook after Q2 results.
- Q2 2026 revenue was approximately $628.7 million, below Wall Street consensus of $652.3 million.
- Q2 2026 EPS of $0.82 missed the consensus estimate of $0.91, a -9.4% miss.
- The guidance reduction was attributed to a slower-than-expected ramp in the neuroendocrine-tumor business.
- The stock declined after the guidance reduction.
Financial Impact
Q2 2026 revenue of ~$628.7M missed consensus of $652.3M; EPS of $0.82 missed consensus of $0.91.
Risk Factors
- Potential shareholder class action lawsuit and associated legal costs.
- Slower-than-expected commercial ramp for the neuroendocrine-tumor business.
- Further negative guidance revisions or operational setbacks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302847550 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | 8-K | $56.12 $58.36 | ▼ −3.99% | ▼ −4.21% | $57.94 (−3.24%) |
Aug 10, 2026 7w ago | Press Release | $51.33 $53.10 | ▼ −3.44% | ▼ −3.85% | $57.94 (−12.88%) |
Jun 3, 2026 17w ago | Insider Cluster | $52.39 $53.50 | ▲ +2.12% | ▲ +4.68% | $57.94 (+10.60%) |
May 29, 2026 17w ago | 8-K | $50.20 $52.70 | ▲ +4.98% | ▲ +7.73% | $57.94 (+15.42%) |
May 28, 2026 18w ago | Insider Cluster | $50.32 $51.60 | ▲ +2.55% | ▲ +2.84% | $57.94 (+15.15%) |
May 28, 2026 18w ago | Insider Cluster | $50.32 $51.60 | ▲ +2.55% | ▲ +2.84% | $57.94 (+15.15%) |
May 28, 2026 18w ago | Insider Cluster | $50.32 $52.69 | ▲ +4.71% | ▲ +7.23% | $57.94 (+15.15%) |
May 22, 2026 18w ago | Insider Cluster | $49.94 $48.49 | ▼ −2.90% | ▼ −4.12% | $57.94 (+16.02%) |
May 19, 2026 19w ago | Insider Cluster | $49.89 $51.46 | ▲ +3.15% | ▲ +1.34% | $57.94 (+16.14%) |
May 7, 2026 21w ago | Insider Cluster | $46.10 $51.29 | ▲ +11.26% | ▲ +9.76% | $57.94 (+25.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access